Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 12

1.

Adverse effects of bisphosphonates: implications for osteoporosis management.

Kennel KA, Drake MT.

Mayo Clin Proc. 2009 Jul;84(7):632-7; quiz 638. doi: 10.1016/S0025-6196(11)60752-0. Review.

2.

Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases.

Park IH, Ro J, Nam BH, Kwon Y, Lee KS.

BMC Cancer. 2009 May 20;9:154. doi: 10.1186/1471-2407-9-154.

3.

Current and future treatments of bone metastases.

Clark JC, Dass CR, Choong PF.

Expert Opin Emerg Drugs. 2008 Dec;13(4):609-27. doi: 10.1517/14728210802584217 . Review.

PMID:
19046130
4.

Exploring the anti-tumour activity of bisphosphonates in early breast cancer.

Winter MC, Holen I, Coleman RE.

Cancer Treat Rev. 2008 Aug;34(5):453-75. doi: 10.1016/j.ctrv.2008.02.004. Review.

PMID:
18423992
5.

Bisphosphonates in cancer therapy.

Stresing V, Daubiné F, Benzaid I, Mönkkönen H, Clézardin P.

Cancer Lett. 2007 Nov 8;257(1):16-35. Epub 2007 Aug 13. Review.

PMID:
17697748
6.
8.

Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis.

Cremers SC, Pillai G, Papapoulos SE.

Clin Pharmacokinet. 2005;44(6):551-70. Review.

PMID:
15932344
9.

Designing proteins for bone targeting.

Gittens SA, Bansal G, Zernicke RF, Uludağ H.

Adv Drug Deliv Rev. 2005 May 25;57(7):1011-36. Epub 2005 Apr 18. Review.

PMID:
15876401
10.

Decimal point--osteoporosis therapy at the 10-year mark.

Strewler GJ.

N Engl J Med. 2004 Mar 18;350(12):1172-4. No abstract available.

PMID:
15028820
11.

Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents.

Hirabayashi H, Fujisaki J.

Clin Pharmacokinet. 2003;42(15):1319-30. Review.

PMID:
14674786
12.

Recent advances in 99mTc radiopharmaceuticals.

Arano Y.

Ann Nucl Med. 2002 Apr;16(2):79-93. Review.

PMID:
12043913

Supplemental Content

Support Center